
-
NovoCure Limited NasdaqGS:NVCR NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Location: Neuhofstrasse 21, Baar, 6340, Switzerland | Website: https://www.novocure.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.762B
Cash
929.1M
Avg Qtr Burn
-7.615M
Short % of Float
5.40%
Insider Ownership
9.71%
Institutional Own.
98.06%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Optune Lua Details Non-small cell lung carcinoma | Approved Update | |
Optune Gio® w/ radiation therapy & temozolomide (TMZ) Details Glioblastoma, Cancer | Phase 3 Data readout | |
Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer | Phase 3 Update | |
Immune checkpoint inhibitors or docetaxel w/ NovoTTF-200T Details Non-small cell lung carcinoma | Phase 3 Update | |
Stereotactic radiosurgery (SRS) w/ NovoTTF-200M Details Brain metastases | Phase 3 Update | |
Paclitaxel w/ NovoTTF-100L(O) Details Ovarian cancer | Phase 3 Update | |
Atezolizumab, Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer, Cancer | Phase 2 Data readout |